— Know what they know.
Not Investment Advice

ELAT NYSE

Elanco Animal Health Inc
1W: -100.0% 1M: -100.0% 3M: -100.0% 1Y: -100.0% 3Y: -100.0%
$21.32
Last traded 2023-02-14 — delisted
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

Cash Flow Trends

Operating Cash Flow
$560M +3.5% ▲
Capital Expenditures
$276M -87.8% ▼
5Y CAGR: -2.4%
Free Cash Flow
$284M -27.9% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$77M -33.6% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$472M-$78M-$1.2B$338M-$232M
Depreciation & Amort.$716M$682M$694M$662M$680M
Stock-Based Comp.$66M$59M$46M$55M$68M
Change in Working Capital-$87M-$462M-$294M$0$0
Other Non-Cash Items$414M$308M$1.1B-$402M$178M
Operating Cash Flow$483M$452M$271M$541M$560M
— Investing Activities —
Capital Expenditures-$197M-$184M-$140M-$147M-$276M
Acquisitions (Net)-$342M$13M-$19M$0$0
Investment Purchases$0$0$0$0$0
Investment Sales$0$0$0$0$0
Other Investing$9M-$8M-$10M$1.3B-$3M
Investing Cash Flow-$530M-$179M-$169M$1.2B-$279M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$210M-$549M-$83M-$1.5B-$275M
Financing Cash Flow$210M-$549M-$83M-$1.5B-$275M
Net Change in Cash$132M-$293M$7M$116M$77M
Cash End of Period$638M$345M$7M$468M$0
Free Cash Flow$286M$268M$131M$394M$284M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms